Monday – 18th November 2024 – Pre-conference Half Day - ET (Eastern Time, GMT-05:00)
Monday – 18th November 2024 – Pre-conference Half Day - ET (Eastern Time, GMT-05:00)
Government programs represent a significant portion of total gross sales and are projected to continue to grow rapidly. Pressure on gross-to-net sales is escalating due to government programs having the highest prescription drug rebates.
Course is designed to enhance knowledge of the Inflation Reduction Act and complex government programs including Medicare, Medicaid, TRICARE & 340B programs.
Numerical examples will be presented to illustrate key concepts and practical application.
By attending this course, you'll learn about:
Medicare Part B buy & bill
White, brown, and clear bagging
Medicare Part D Prescription Drug Program
Implications of Inflation Reduction Act Three Pillars (Medicare Price Negotiation, Inflation Rebates & Benefit Redesign)
Considerations for estimating Medicare Part D Donut Hole
Medicaid Drug Rebate Program
Implications of price increases on Medicaid Net Price and GTN
Triggering Medicaid best price penalty
Medicaid AMP-Cap removal
Charitable foundations
Prescriptions with negative net sales
Branded prescription drug fee
Authorized generics
TRICARE
340B – ecosystem, double-dipping and current developments
*Additional fee to participate
CPE Credits Available: 2.0
- Murray Kay - Former Senior Vice President and Chief Financial Officer, Solvay Pharmaceuticals and Former Commercial Controller, AbbVie
This in-depth panel is ideal for anyone with responsibilities around gross-to-net and for companies that are pre-revenue or early-stage revenue.
CPE Credits Available: 1.2
- Tim Nugent - Managing Director, Baker Tilly
- Kinneret Klein - Executive Director, Commercial Financial Planning & Analysis, Biocryst
- Meera Phaltankar - Director of Revenue Accounting, Ironshore Pharmaceuticals, Inc.
10 Hot Topic Tables:
1. Returns: Successful Vendors, Analogs and Methodologies
2. Government Impacts on GTN: IRA Part D/B Rebates, MFP & AMP Cap Removal
3. Coverage Gap Redesign: Successful Predictive Modeling
4. GTN Monthly Close: Successful Practices & Methodologies.
5. All Things 340B: Analyzing Revenue Leakage & Tackling Contract Pharmacies
6. Wrangling GTN Data Sources: 3PL, Copay Vendor, ERP, Adjudication Application.
7. Patient & Access Program Impacts on GTN: Copay, Bridge, Voucher, Digital Pharmacies
8. Payer Pressures on GTN: Understanding Shifts in Rebates, Admin Fees & Price Protection Protection
9. Demand & Inventory Mgt: Reconciling Pipeline against Sales and Demand
10. Product Launch: Successful GTN Roadmap to Launch.
Facilitated by Jen Sharpe and the Revenue Analytics Collaborative, sponsored by IntegriChain
CPE Credits Available: 1.8
- Jennifer Sharpe - Vice President, Gross-to-Net Consulting and Facilitator, Revenue Analytics Collaborative, IntegriChain